Bioventus expands hyaluronic acid product for osteoarthritis into Australia, New Zealand

Bioventus plans to expand Durolane, its hyaluronic acid joint-fluid osteoarthritis injection, into Australia and New Zealand.

Advertisement

Four things to know:

1. Durolane is used in the symptomatic treatment of mild to moderate hip osteoarthritis and mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers and toes.

2. The orthobiologic company is also launching another HA-based product, Durolane SJ, in both countries later this year.

3. Durolane SJ is used in the symptomatic treatment of mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers and toes.

4. Both products are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within three months of the operation.

More articles on biologics:
Laser Spine Institute co-founders now owe ex-business partner $300M+, judge rules
Academic panel to define best practices for outpatient stem cell procedure
The big trends, issues in spine shaping practices today

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Biologics

Advertisement

Comments are closed.